The 14‐day repeated‐dose toxicity study of a fixed‐dose combination, QXOH/levobupivacaine, via subcutaneous injection in beagle dogs
- 12 November 2020
- journal article
- research article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 41 (8) , 1241-1261
Abstract
QXOH‐Levobupivacaine (LB) is a fixed‐dose combination of 35‐mM QXOH and 10‐mM LB. It was developed for perioperative analgesia because of its long‐acting analgesic effect. The purpose of this study was to evaluate the potential toxicity of QXOH‐LB in beagle dogs in accordance with the Guidance on the repeated‐dose toxicity published by the China Food and Drug Administration. Groups of five male and five female beagle dogs received normal saline, QXOH‐LB (2, 4, and 8 mg/kg, calculated as QXOH), QXOH (2, 4, and 8 mg/kg), or LB (2 mg/kg, equals the concentration of LB in 8‐mg/kg QXOH‐LB group) at the volume of 1 mL/kg once per day for 14 days through subcutaneous injection. No mortality was observed. Dogs in the control group as well as animals treated with 2‐mg/kg QXOH or QXOH‐LB exhibited normal behaviors. Clinical signs of toxicity in dogs treated with 4 and 8 mg/kg of QXOH or QXOH‐LB included decreased activity, unsteady gait, jerks, tremors, vocalization, emesis, ataxia, lateral/sternal recumbency, deep/rapid respiration, and gasping. Additionally, neurological function was found to be affected by QXOH and QXOH‐LB at the doses of 4 and 8 mg/kg. All clinical signs were recovered within 24 h. The no‐observed‐adverse‐effect level of QXOH and QXOH‐LB was considered to be 2 mg/kg. Toxicokinetic data showed that exposure to QXOH and LB increased as QXOH‐LB doses were increased from 4 to 8 mg/kg. There was no evidence of drug accumulation or any effect of gender.Keywords
Funding Information
- Sichuan Provincial Science and Technology Support Program (2020YJ0053)
- China Postdoctoral Science Foundation (2020M673235)
This publication has 23 references indexed in Scilit:
- Postoperative Pain ControlSurgical Clinics of North America, 2015
- Bupivacaine‐induced cellular entry of QX‐314 and its contribution to differential nerve blockBritish Journal of Pharmacology, 2013
- Duration and Local Toxicity of Sciatic Nerve Blockade With Coinjected Site 1 Sodium-Channel Blockers and Quaternary Lidocaine DerivativesRegional Anesthesia & Pain Medicine, 2012
- Targeting of sodium channel blockers into nociceptors to produce long-duration analgesia: a systematic study and reviewBritish Journal of Pharmacology, 2011
- Prolonged sensory-selective nerve blockadeProceedings of the National Academy of Sciences, 2010
- QX-314 Produces Long-lasting Local Anesthesia Modulated by Transient Receptor Potential Vanilloid Receptors in MiceAnesthesiology, 2009
- Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterionPharmaceutical Statistics, 2008
- The Quaternary Lidocaine Derivative, QX-314, Produces Long-lasting Local Anesthesia in Animal Models In VivoAnesthesiology, 2007
- A Functional Observational Battery for Use in Canine Toxicity Studies: Development and ValidationInternational Journal of Toxicology, 2003
- Adverse Effects and Drug Interactions Associated with Local and Regional AnaesthesiaDrug Safety, 1998